「toxicity」の検索結果

Validate proposed or existing backlinks for relevance, editorial legitimacy, link attributes, spam/toxicity risk, platform compliance, anchor quality, target-page fit, and monitoring evidence. Use this skill when the user asks whether an external link opportunity or placed backlink is safe and useful, and reject toxic, irrelevant, paid-undisclosed, fake, or spam placements.

日本語の概要は準備中です。原文の説明を表示しています。

Field identification of fungi using morphological features, spore prints, habitat analysis, and seasonal context with a safety-first approach. Covers cap, gill, stem, and spore characteristics, look-alike differentiation, toxicity risk assessment, and the critical rule of absolute certainty before consumption. Use when encountering an unknown fungus, foraging for edible mushrooms and needing to confirm species before consumption, assessing whether fungi in a garden or property are harmful, or differentiating an edible species from a dangerous look-alike.

日本語の概要は準備中です。原文の説明を表示しています。

Turn a set of structures into absorption, distribution, metabolism, excretion, and toxicity estimates with ADMET-AI, and read them as a developability verdict rather than a table of numbers. Use this skill to run batch prediction over a library, interpret each endpoint against its DrugBank-approved percentile, and flag the liabilities that stop a series — hERG blockade, CYP inhibition, poor Caco-2 permeability, high clearance, and plasma protein binding. Also trigger on ADMET-AI, admet_ai, Chemprop-RDKit, hERG liability, CYP3A4 inhibition, Caco-2, bioavailability prediction, or developability triage.

日本語の概要は準備中です。原文の説明を表示しています。

Molecular ML with diverse featurizers and pre-built datasets. Use for property prediction (ADMET, toxicity) with traditional ML or GNNs when you want extensive featurization options and MoleculeNet benchmarks. Best for quick experiments with pre-trained models, diverse molecular representations. For ready-made ADMET numbers without training a model use admet-prediction; for benchmark datasets and task-aware splits use pytdc.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a task needs the judgment of a board-certified anesthesiologist — building a preoperative anesthesia plan and risk stratification, choosing general vs. regional technique and airway strategy, managing an intraoperative crisis (difficult airway, malignant hyperthermia, local anesthetic systemic toxicity), or writing a PACU handoff and postoperative pain-management order set.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a task needs the judgment of a Certified Anesthesiologist Assistant (CAA) working inside an Anesthesia Care Team — building and executing an intraoperative anesthetic plan under a directing anesthesiologist, reading a vital-sign trend for anesthesia-specific emergencies (malignant hyperthermia, local anesthetic systemic toxicity, awareness), deciding when a deviation is an immediate-escalation trigger versus an independently correctable event, or navigating the jurisdiction/concurrency limits of CAA practice.

日本語の概要は準備中です。原文の説明を表示しています。

Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.

日本語の概要は準備中です。原文の説明を表示しています。

Screen a hypercalcemic patient for medication- and supplement-induced causes — thiazides, lithium, vitamin D, vitamin A/retinoids, antiestrogens, theophylline, milk-alkali, SGLT2 inhibitors, immune checkpoint inhibitors, denosumab rebound, teriparatide/abaloparatide, foscarnet, ketogenic diet, aluminium. Trigger when a clinician asks "is this hypercalcemia drug-induced", "thiazide hypercalcemia", "lithium hypercalcemia", "denosumab rebound hypercalcemia", "vitamin D toxicity", "milk-alkali syndrome", "SGLT2 hypercalcemia", or any new hypercalcemia where medication review is needed.

日本語の概要は準備中です。原文の説明を表示しています。

Molecular ML with diverse featurizers and pre-built datasets. Use for property prediction (ADMET, toxicity) with traditional ML or GNNs when you want extensive featurization options and MoleculeNet benchmarks. Best for quick experiments with pre-trained models, diverse molecular representations. For graph-first PyTorch workflows use torchdrug; for benchmark datasets use pytdc.

日本語の概要は準備中です。原文の説明を表示しています。

ADMET property prediction for drug candidates. Full pharmacokinetic panel (Caco-2, PPB, clearance, CYP), toxicity (hERG, AMES, DILI), drug-likeness (Lipinski, QED), using RDKit descriptors and TDC models.

日本語の概要は準備中です。原文の説明を表示しています。

Interpretable ADMET analysis with mechanistic reasoning. Maps liabilities to structural causes and biological pathways. Based on CoTox (Park 2025) and DrugR (Liu 2026).

日本語の概要は準備中です。原文の説明を表示しています。

Therapeutics Data Commons. AI-ready drug discovery datasets (ADME, toxicity, DTI), benchmarks, scaffold splits, molecular oracles, for therapeutic ML and pharmacological prediction.

日本語の概要は準備中です。原文の説明を表示しています。

Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.

日本語の概要は準備中です。原文の説明を表示しています。

Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.

日本語の概要は準備中です。原文の説明を表示しています。